Comprehensive Meta-Analysis on Drug-Eluting Stents versus Bare-Metal Stents during Extended Follow-up

Henri Roukoz, Anthony A. Bavry, Michael L. Sarkees, Girish R. Mood, Dharam J. Kumbhani, Mark G. Rabbat, Deepak L. Bhatt

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Background: Several observational reports have documented both increased and decreased cardiac mortality or Q-wave myocardial infarction with drug-eluting stents compared with bare-metal stents. Methods: We sought to evaluate the safety and efficacy of drug-eluting stents compared with bare-metal stents early after intervention (<1 year) and late (>1 year) among a broad population of patients, using a meta-analysis of randomized clinical trials. Results: We identified 28 trials with a total of 10,727 patients and a mean follow-up of 29.6 months. For early outcomes (<1 year), all-cause mortality for drug-eluting stents versus bare-metal stents was 2.1% versus 2.4% (risk ratio [RR] 0.91, [95% confidence interval (CI), 0.70-1.18]; P = .47), non-Q-wave myocardial infarction was 3.3% versus 4.4% (RR 0.78 [95% CI, 0.61-1.00]; P = .055), target lesion revascularization was 5.8% versus 18.4% (RR 0.28 [95% CI, 0.21-0.38]; P <.001), and stent thrombosis was 1.1% versus 1.3% (RR 0.87 [95% CI, 0.60-1.26]; P = .47). For late outcomes (>1 year), all-cause mortality for drug-eluting stents versus bare-metal stents was 5.9% versus 5.7% (RR 1.03 [95% CI, 0.83-1.28]; P = .79), target lesion revascularization was 4.0% versus 3.3% (RR 1.22 [95% CI, 0.92-1.60]; P = .16), non-Q-wave myocardial infarction was 1.6% versus 1.2% (RR 1.36 [95% CI, 0.74-2.53]; P = .32) and stent thrombosis was 0.7% versus 0.1% (RR 4.57 [95% CI, 1.54-13.57]; P = .006). Conclusions: There was no excess mortality with drug-eluting stents. Within 1 year, drug-eluting stents appear to be safe and efficacious with possibly decreased non-Q-wave myocardial infarction compared with bare-metal stents. After 1 year, drug-eluting stents still have similar mortality, despite increased stent thrombosis. The reduction in target lesion revascularization with drug-eluting stents mainly happens within 1 year, but is sustained thereafter.

Original languageEnglish (US)
JournalAmerican Journal of Medicine
Volume122
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Drug-Eluting Stents
Stents
Meta-Analysis
Metals
Mortality
Myocardial Infarction
Thrombosis
Randomized Controlled Trials
Safety
Population

Keywords

  • Bare-metal stent
  • Drug-eluting stent
  • Percutaneous coronary intervention
  • Stent thrombosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Comprehensive Meta-Analysis on Drug-Eluting Stents versus Bare-Metal Stents during Extended Follow-up. / Roukoz, Henri; Bavry, Anthony A.; Sarkees, Michael L.; Mood, Girish R.; Kumbhani, Dharam J.; Rabbat, Mark G.; Bhatt, Deepak L.

In: American Journal of Medicine, Vol. 122, No. 6, 06.2009.

Research output: Contribution to journalArticle

Roukoz, Henri ; Bavry, Anthony A. ; Sarkees, Michael L. ; Mood, Girish R. ; Kumbhani, Dharam J. ; Rabbat, Mark G. ; Bhatt, Deepak L. / Comprehensive Meta-Analysis on Drug-Eluting Stents versus Bare-Metal Stents during Extended Follow-up. In: American Journal of Medicine. 2009 ; Vol. 122, No. 6.
@article{37b8eec69d8747489cf4aeb0676a7263,
title = "Comprehensive Meta-Analysis on Drug-Eluting Stents versus Bare-Metal Stents during Extended Follow-up",
abstract = "Background: Several observational reports have documented both increased and decreased cardiac mortality or Q-wave myocardial infarction with drug-eluting stents compared with bare-metal stents. Methods: We sought to evaluate the safety and efficacy of drug-eluting stents compared with bare-metal stents early after intervention (<1 year) and late (>1 year) among a broad population of patients, using a meta-analysis of randomized clinical trials. Results: We identified 28 trials with a total of 10,727 patients and a mean follow-up of 29.6 months. For early outcomes (<1 year), all-cause mortality for drug-eluting stents versus bare-metal stents was 2.1{\%} versus 2.4{\%} (risk ratio [RR] 0.91, [95{\%} confidence interval (CI), 0.70-1.18]; P = .47), non-Q-wave myocardial infarction was 3.3{\%} versus 4.4{\%} (RR 0.78 [95{\%} CI, 0.61-1.00]; P = .055), target lesion revascularization was 5.8{\%} versus 18.4{\%} (RR 0.28 [95{\%} CI, 0.21-0.38]; P <.001), and stent thrombosis was 1.1{\%} versus 1.3{\%} (RR 0.87 [95{\%} CI, 0.60-1.26]; P = .47). For late outcomes (>1 year), all-cause mortality for drug-eluting stents versus bare-metal stents was 5.9{\%} versus 5.7{\%} (RR 1.03 [95{\%} CI, 0.83-1.28]; P = .79), target lesion revascularization was 4.0{\%} versus 3.3{\%} (RR 1.22 [95{\%} CI, 0.92-1.60]; P = .16), non-Q-wave myocardial infarction was 1.6{\%} versus 1.2{\%} (RR 1.36 [95{\%} CI, 0.74-2.53]; P = .32) and stent thrombosis was 0.7{\%} versus 0.1{\%} (RR 4.57 [95{\%} CI, 1.54-13.57]; P = .006). Conclusions: There was no excess mortality with drug-eluting stents. Within 1 year, drug-eluting stents appear to be safe and efficacious with possibly decreased non-Q-wave myocardial infarction compared with bare-metal stents. After 1 year, drug-eluting stents still have similar mortality, despite increased stent thrombosis. The reduction in target lesion revascularization with drug-eluting stents mainly happens within 1 year, but is sustained thereafter.",
keywords = "Bare-metal stent, Drug-eluting stent, Percutaneous coronary intervention, Stent thrombosis",
author = "Henri Roukoz and Bavry, {Anthony A.} and Sarkees, {Michael L.} and Mood, {Girish R.} and Kumbhani, {Dharam J.} and Rabbat, {Mark G.} and Bhatt, {Deepak L.}",
year = "2009",
month = "6",
doi = "10.1016/j.amjmed.2008.12.019",
language = "English (US)",
volume = "122",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Comprehensive Meta-Analysis on Drug-Eluting Stents versus Bare-Metal Stents during Extended Follow-up

AU - Roukoz, Henri

AU - Bavry, Anthony A.

AU - Sarkees, Michael L.

AU - Mood, Girish R.

AU - Kumbhani, Dharam J.

AU - Rabbat, Mark G.

AU - Bhatt, Deepak L.

PY - 2009/6

Y1 - 2009/6

N2 - Background: Several observational reports have documented both increased and decreased cardiac mortality or Q-wave myocardial infarction with drug-eluting stents compared with bare-metal stents. Methods: We sought to evaluate the safety and efficacy of drug-eluting stents compared with bare-metal stents early after intervention (<1 year) and late (>1 year) among a broad population of patients, using a meta-analysis of randomized clinical trials. Results: We identified 28 trials with a total of 10,727 patients and a mean follow-up of 29.6 months. For early outcomes (<1 year), all-cause mortality for drug-eluting stents versus bare-metal stents was 2.1% versus 2.4% (risk ratio [RR] 0.91, [95% confidence interval (CI), 0.70-1.18]; P = .47), non-Q-wave myocardial infarction was 3.3% versus 4.4% (RR 0.78 [95% CI, 0.61-1.00]; P = .055), target lesion revascularization was 5.8% versus 18.4% (RR 0.28 [95% CI, 0.21-0.38]; P <.001), and stent thrombosis was 1.1% versus 1.3% (RR 0.87 [95% CI, 0.60-1.26]; P = .47). For late outcomes (>1 year), all-cause mortality for drug-eluting stents versus bare-metal stents was 5.9% versus 5.7% (RR 1.03 [95% CI, 0.83-1.28]; P = .79), target lesion revascularization was 4.0% versus 3.3% (RR 1.22 [95% CI, 0.92-1.60]; P = .16), non-Q-wave myocardial infarction was 1.6% versus 1.2% (RR 1.36 [95% CI, 0.74-2.53]; P = .32) and stent thrombosis was 0.7% versus 0.1% (RR 4.57 [95% CI, 1.54-13.57]; P = .006). Conclusions: There was no excess mortality with drug-eluting stents. Within 1 year, drug-eluting stents appear to be safe and efficacious with possibly decreased non-Q-wave myocardial infarction compared with bare-metal stents. After 1 year, drug-eluting stents still have similar mortality, despite increased stent thrombosis. The reduction in target lesion revascularization with drug-eluting stents mainly happens within 1 year, but is sustained thereafter.

AB - Background: Several observational reports have documented both increased and decreased cardiac mortality or Q-wave myocardial infarction with drug-eluting stents compared with bare-metal stents. Methods: We sought to evaluate the safety and efficacy of drug-eluting stents compared with bare-metal stents early after intervention (<1 year) and late (>1 year) among a broad population of patients, using a meta-analysis of randomized clinical trials. Results: We identified 28 trials with a total of 10,727 patients and a mean follow-up of 29.6 months. For early outcomes (<1 year), all-cause mortality for drug-eluting stents versus bare-metal stents was 2.1% versus 2.4% (risk ratio [RR] 0.91, [95% confidence interval (CI), 0.70-1.18]; P = .47), non-Q-wave myocardial infarction was 3.3% versus 4.4% (RR 0.78 [95% CI, 0.61-1.00]; P = .055), target lesion revascularization was 5.8% versus 18.4% (RR 0.28 [95% CI, 0.21-0.38]; P <.001), and stent thrombosis was 1.1% versus 1.3% (RR 0.87 [95% CI, 0.60-1.26]; P = .47). For late outcomes (>1 year), all-cause mortality for drug-eluting stents versus bare-metal stents was 5.9% versus 5.7% (RR 1.03 [95% CI, 0.83-1.28]; P = .79), target lesion revascularization was 4.0% versus 3.3% (RR 1.22 [95% CI, 0.92-1.60]; P = .16), non-Q-wave myocardial infarction was 1.6% versus 1.2% (RR 1.36 [95% CI, 0.74-2.53]; P = .32) and stent thrombosis was 0.7% versus 0.1% (RR 4.57 [95% CI, 1.54-13.57]; P = .006). Conclusions: There was no excess mortality with drug-eluting stents. Within 1 year, drug-eluting stents appear to be safe and efficacious with possibly decreased non-Q-wave myocardial infarction compared with bare-metal stents. After 1 year, drug-eluting stents still have similar mortality, despite increased stent thrombosis. The reduction in target lesion revascularization with drug-eluting stents mainly happens within 1 year, but is sustained thereafter.

KW - Bare-metal stent

KW - Drug-eluting stent

KW - Percutaneous coronary intervention

KW - Stent thrombosis

UR - http://www.scopus.com/inward/record.url?scp=66149158178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149158178&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2008.12.019

DO - 10.1016/j.amjmed.2008.12.019

M3 - Article

C2 - 19486720

AN - SCOPUS:66149158178

VL - 122

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 6

ER -